Tempest Therapeutics Inc (TPST)

$1.79 -0.01 (-0.56%)
Market Cap 25.82M
Revenue (ttm) 0.00
Net Income (ttm) -26.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 99,900
Avg Vol 207,116
Day's Range N/A - N/A
Shares Out 14.34M
Stochastic %K 4%
Beta -2.00
Analysts Strong Sell
Price Target $11.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
lousjamsession
lousjamsession Apr. 25 at 3:53 PM
$TPST not too shabby for a Saturday
0 · Reply
Michl2000
Michl2000 Apr. 24 at 7:42 PM
$TPST
1 · Reply
JonDsoCal
JonDsoCal Apr. 24 at 6:56 PM
$TPST When we saw it was you, we turned off all the lights and hid behind the couch hoping you'd leave.
1 · Reply
Michl2000
Michl2000 Apr. 24 at 4:47 PM
$TPST
0 · Reply
lousjamsession
lousjamsession Apr. 23 at 9:34 PM
$TPST
0 · Reply
Xamayca
Xamayca Apr. 23 at 6:19 PM
$TPST Nobody home?
1 · Reply
Michl2000
Michl2000 Apr. 23 at 5:39 PM
$TPST waiting for the next reverse split 🤷🥱
0 · Reply
saddy12345
saddy12345 Apr. 23 at 10:53 AM
$TPST This turd is going unde 1.5$ today. Good luck
1 · Reply
lousjamsession
lousjamsession Apr. 22 at 3:20 PM
$TPST
1 · Reply
TwongStocks
TwongStocks Apr. 22 at 12:06 PM
$TPST From their most recent investor presentation, the 2003 tech transfer is scheduled to be completed in Q3, with the US IND and Phase 2 b enrollment expected in Q4 (screenshot). From the PR --> "Earlier this month, Tempest’s manufacturing partner, Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”), took delivery of the TPST-2003 lentiviral vector, a critical component used in the manufacturing of TPST-2003. This milestone supports Tempest’s plans to initiate the first potentially registrational study to evaluate a dual-targeting CAR-T therapy in patients with rrMM, including patients who are experiencing extramedullary disease (“EMD”), later this year."
0 · Reply
Latest News on TPST
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Apr 22, 2026, 8:00 AM EDT - 3 days ago

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Apr 14, 2026, 8:00 AM EDT - 11 days ago

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Mar 30, 2026, 9:00 AM EDT - 26 days ago

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Tempest Therapeutics Announces Up To $6 Million Private Placement

Mar 23, 2026, 8:00 AM EDT - 4 weeks ago

Tempest Therapeutics Announces Up To $6 Million Private Placement

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Mar 11, 2026, 8:00 AM EDT - 6 weeks ago

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Feb 25, 2026, 7:59 AM EST - 2 months ago

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Feb 11, 2026, 6:59 AM EST - 2 months ago

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Feb 4, 2026, 4:47 PM EST - 2 months ago

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Jan 20, 2026, 5:20 PM EST - 3 months ago

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 26, 2025, 4:05 PM EST - 5 months ago

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 8:00 AM EST - 5 months ago

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

Nov 19, 2025, 9:00 AM EST - 5 months ago

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

BTX

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:30 AM EST - 6 months ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:12 PM EDT - 9 months ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 30, 2025, 8:00 AM EDT - 10 months ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 11, 2025, 8:00 AM EDT - 11 months ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Jun 5, 2025, 8:00 AM EDT - 11 months ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:28 PM EDT - 1 year ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Apr 9, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:10 PM EDT - 1 year ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Mar 13, 2025, 8:00 AM EDT - 1 year ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 10, 2025, 8:00 AM EST - 1 year ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:30 PM EST - 1 year ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Jan 6, 2025, 8:00 AM EST - 1 year ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 9:00 AM EST - 1 year ago

Tempest Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 1 year ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:21 PM EST - 1 year ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Oct 10, 2024, 9:06 AM EDT - 1 year ago

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Oct 10, 2024, 7:01 AM EDT - 1 year ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:30 PM EDT - 1 year ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Tempest Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:56 PM EDT - 1 year ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Jun 20, 2024, 9:43 AM EDT - 2 years ago

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Tempest Therapeutics Transcript: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Transcript: Study Update

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 18, 2024, 6:22 PM EDT - 2 years ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Tempest Therapeutics Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: Jefferies Global Healthcare Conference

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 31, 2024, 3:45 PM EDT - 2 years ago

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 29, 2024, 2:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:29 PM EDT - 2 years ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 2 years ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:25 PM EDT - 2 years ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 2 years ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 9:10 AM EST - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Tempest Therapeutics Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 28, 2023, 3:00 PM EST - 2 years ago

Tempest Therapeutics Transcript: Piper Sandler 35th Annual Healthcare Conference

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 2 years ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 5:17 PM EST - 2 years ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 12:29 PM EDT - 2 years ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Tempest Therapeutics Transcript: Study Result

Oct 11, 2023, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Transcript: Study Result

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:01 AM EDT - 2 years ago

Tempest Adopts Limited Duration Stockholder Rights Plan

Tempest Therapeutics Transcript: Study Result

Jun 5, 2022, 7:30 AM EDT - 4 years ago

Tempest Therapeutics Transcript: Study Result

lousjamsession
lousjamsession Apr. 25 at 3:53 PM
$TPST not too shabby for a Saturday
0 · Reply
Michl2000
Michl2000 Apr. 24 at 7:42 PM
$TPST
1 · Reply
JonDsoCal
JonDsoCal Apr. 24 at 6:56 PM
$TPST When we saw it was you, we turned off all the lights and hid behind the couch hoping you'd leave.
1 · Reply
Michl2000
Michl2000 Apr. 24 at 4:47 PM
$TPST
0 · Reply
lousjamsession
lousjamsession Apr. 23 at 9:34 PM
$TPST
0 · Reply
Xamayca
Xamayca Apr. 23 at 6:19 PM
$TPST Nobody home?
1 · Reply
Michl2000
Michl2000 Apr. 23 at 5:39 PM
$TPST waiting for the next reverse split 🤷🥱
0 · Reply
saddy12345
saddy12345 Apr. 23 at 10:53 AM
$TPST This turd is going unde 1.5$ today. Good luck
1 · Reply
lousjamsession
lousjamsession Apr. 22 at 3:20 PM
$TPST
1 · Reply
TwongStocks
TwongStocks Apr. 22 at 12:06 PM
$TPST From their most recent investor presentation, the 2003 tech transfer is scheduled to be completed in Q3, with the US IND and Phase 2 b enrollment expected in Q4 (screenshot). From the PR --> "Earlier this month, Tempest’s manufacturing partner, Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”), took delivery of the TPST-2003 lentiviral vector, a critical component used in the manufacturing of TPST-2003. This milestone supports Tempest’s plans to initiate the first potentially registrational study to evaluate a dual-targeting CAR-T therapy in patients with rrMM, including patients who are experiencing extramedullary disease (“EMD”), later this year."
0 · Reply
TwongStocks
TwongStocks Apr. 22 at 12:03 PM
$TPST Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T https://ir.tempesttx.com/news-releases/news-release-details/tempest-announces-key-manufacturing-milestone-tpst-2003-dual • Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development • Tech transfer on track to support initiation of potentially registrational study in Q4 2026
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 22 at 9:07 AM
$TPST
0 · Reply
Xamayca
Xamayca Apr. 22 at 12:02 AM
$TPST This is undoubtedly a shakeout , whatever my broker saw to remove my electronic trading ability was apparent to them as manipulation I’m not making this up (Schwab) If it dips tomorrow it’s dry powder time for me
0 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Apr. 21 at 8:38 PM
$TPST Not worried Normal action for a small cap bio with no sales, revenue or cash
0 · Reply
lousjamsession
lousjamsession Apr. 21 at 8:21 PM
$TPST Tomorrow marks the final day of the AACR (American Association for Cancer Research) Annual Meeting 2026 in San Diego.While TPST isn't presenting tomorrow, other HCC (liver cancer) data has been trickling out from competitors (like Rznomics' RNA therapy results). Significant movement in the biotech sector often happens as the conference closes and institutional investors rebalance positions based on the week’s findings.rank TPST in the top 10% of the market for maximum volatility. Expect sharp swings during tomorrow's session, especially in the first and last hour of trading.The company recently (April 14) appointed Dr. Andrew Fang as Head of Business Development. His primary focus is securing strategic partnerships for the amezalpat Phase 3 program, specifically targeting the China market.While unlikely for tomorrow specifically, any "leak" or official PR regarding a licensing deal or bridge financing would be the primary catalyst to push the stock.
2 · Reply
Xamayca
Xamayca Apr. 21 at 7:54 PM
$TPST Lol well maybe! Adding when that gap fills
0 · Reply
Michl2000
Michl2000 Apr. 21 at 7:49 PM
$TPST 💩💩💩
0 · Reply
Michl2000
Michl2000 Apr. 21 at 3:21 PM
$TPST hopium story - nothing else.
0 · Reply
claybridge
claybridge Apr. 21 at 3:09 PM
$TPST am I looking stupid yet?
1 · Reply
Onedaytolive
Onedaytolive Apr. 21 at 3:34 AM
$TPST While charts are important, I tend to focus on market capitalization. I believe that once the value of KQ2003 is recognized, its market cap will quickly reach $100 million to $300 million. The angel investor used $15 million—money he had saved his entire life—to make an early-stage investment in Novatim’s KQ2003, purchasing rights to the drug in many regions. Angel took even greater risks than we did to acquire KQ2003 and TPST. We are essentially betting on the gamble he has staked his life on. Needless to say, he is a CAR-T specialist whom MIT is proud to count among its alumni. What drove him to take such action was the wrongful conduct committed by a subsidiary of AstraZeneca.
0 · Reply
Michl2000
Michl2000 Apr. 20 at 6:28 PM
$TPST traditional always downwards
0 · Reply
lousjamsession
lousjamsession Apr. 20 at 5:41 PM
$TPST this thing isn't stable yet but the dark yellow dotted line is the current projection but due to market shenanigans the range between bottom and its peak its pretty wide meaning it can go either way. Next earnings should guide us to have a better idea. From a technical aspect its bearish but on fundamentals things can change quickly to be bullish. I like the odds on the latter. Difference between Brady and Angel. Brady spent weeks and months in silence dik teasing shareholders on a small time youtube show with a handful of views where Angel has been in motion since he took charge so i like where its going.
1 · Reply